Maze Therapeutics (NASDAQ:MAZE) Upgraded at Leerink Partnrs

Leerink Partnrs upgraded shares of Maze Therapeutics (NASDAQ:MAZE) to a strong-buy rating in a report released on Tuesday,Zacks.com reports. Leerink Partnrs also issued estimates for Maze Therapeutics’ Q4 2024 earnings at ($7.60) EPS, FY2024 earnings at ($4.93) EPS, Q1 2025 earnings at ($0.58) EPS, Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.59) EPS, Q4 2025 earnings at ($0.60) EPS, FY2025 earnings at ($2.07) EPS, FY2026 earnings at ($2.63) EPS, FY2027 earnings at ($2.52) EPS, FY2028 earnings at ($2.72) EPS and FY2029 earnings at ($3.17) EPS.

A number of other research firms also recently weighed in on MAZE. Leerink Partners began coverage on Maze Therapeutics in a research note on Tuesday. They issued an “outperform” rating and a $28.00 price target on the stock. JPMorgan Chase & Co. initiated coverage on shares of Maze Therapeutics in a research report on Tuesday. They set an “overweight” rating and a $30.00 target price on the stock. Finally, Guggenheim assumed coverage on shares of Maze Therapeutics in a report on Tuesday. They issued a “buy” rating and a $19.00 price target for the company. Three analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $25.67.

Maze Therapeutics Price Performance

Shares of Maze Therapeutics stock opened at $12.72 on Tuesday. Maze Therapeutics has a 52-week low of $10.08 and a 52-week high of $17.00.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.